Epicrispr Biotechnologies has secured $68 million in Series B financing to support the clinical development of its disease-modifying therapy EPI-321. The financing was led by Ally Bridge Group with participation from SOLVE FSHD.
Amount Raised
$68 Million
Round Type
Series B
South San FranciscoBiotechnologyHealth CareGeneticsTherapeuticsInvestors
Description
Epicrispr Biotechnologies, a biotechnology company focused on developing curative therapies, has announced it secured $68 million in the first close of its Series B financing. The proceeds will be used for the clinical development of EPI-321, aiming to treat facioscapulohumeral muscular dystrophy (FSHD). The Series B was led by Ally Bridge Group, with participation from SOLVE FSHD and other investors. The clinical trial is expected to begin in 2025 in New Zealand.
Quick answer
Epicrispr Biotechnologies raised $68 Million in a Series B round, dated March 27, 2025. Investors: Solve Fshd and Ally Bridge Group. Epicrispr Biotechnologies is based in South San Francisco, California, United States.
- How much did Epicrispr Biotechnologies raise?
- Epicrispr Biotechnologies raised $68 Million in a Series B round on March 27, 2025.
- Who invested in Epicrispr Biotechnologies?
- Solve Fshd and Ally Bridge Group are named as investors in this round.
- What does Epicrispr Biotechnologies do?
- Epicrispr Biotechnologies is a biotechnology company focused on developing curative therapies for genetic neuromuscular diseases.
- Where is Epicrispr Biotechnologies based and how big is it?
- Epicrispr Biotechnologies is based in South San Francisco, California, United States. Fundz records about 38 employees.
Source: Fundz verified event record.
Who else raised in Genetics and Therapeutics around the same time
Companies in the same sectors as Epicrispr Biotechnologies that raised within 45 days of this round, from Fundz verified event records.
- Junevity raised $10M (Seed) on February 13, 2025.
- Cellestial Health raised an undisclosed amount (Pre-Seed) on May 9, 2025.
- ImmuneWalk Therapeutics raised $7M (Seed) on May 8, 2025.
- PAQ Therapeutics raised $39M (Series B) on May 7, 2025.
- Avammune Therapeutics raised $12M (Series A) on May 7, 2025.
- Paradigm Therapeutics raised $13M (Funding Round) on May 6, 2025.
Who to call at Epicrispr Biotechnologies, and when
A new round usually means Epicrispr Biotechnologies is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Epicrispr Biotechnologies raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Epicrispr Biotechnologies, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Epicrispr Biotechnologies. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Epicrispr Biotechnologies raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansEpicrispr Biotechnologies raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.